Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB-300 in metastatic castration-resistant prostate cancer
NCT05553639Phase 2Terminated
- Sponsor
- HOOKIPA Pharma
- Start
- May 2023
- Primary completion
- Apr 2024
- Modality
- Viral Vector Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HB-300 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by HOOKIPA Pharma. Primary endpoints: Safety and Tolerability (Phase 1) at 6 months and Recommended Phase 2 Dose at 6 months. Started May 2023; status: terminated.
02
Drugs
HB-300
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05553639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05553639.